UCB and Biogen Idec (Nasdaq: BIIB) announced the discontinuation of the Phase II clinical trial of CDP323 for the treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE